Novel adenosine 5′-triphosphate-sensitive potassium channel ligands: A patent overview (2005 - 2010)

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 3, 2011, Pages 355-379

  Rapposelli, Simona ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

ATP sensitive potassium channel; KATP blocker; KATP channel ligands; KATP channel modulator; KCOs; mito KATP channel opener

Indexed keywords

4 SPIROCYCLE BENZOPYRAN DERIVATIVE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL OPENER; APRIKALIM; BENZOPYRAN DERIVATIVE; BIMAKALIM; CANNABINOID RECEPTOR AFFECTING AGENT; CROMAKALIM; DIAZOXIDE; DIHYDROPYRIDINE; GLIBENCLAMIDE; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; METFORMIN; METHANOL; MINOXIDIL; MORPHINE; NICORANDIL; PINACIDIL; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL BLOCKING AGENT; REACTIVE OXYGEN METABOLITE; TERTIARY CARBINOL DERIVATIVE; UNCLASSIFIED DRUG;

ALOPECIA; ANGINA PECTORIS; ANTINOCICEPTION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; EDEMA; ENERGY EXPENDITURE; FATIGUE; GLUCOSE TRANSPORT; HEART CONTRACTION; HEART MUSCLE CELL; HEART PROTECTION; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MITOCHONDRION SWELLING; MOLECULAR PROBE; NERVE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVERACTIVE BLADDER; PATENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SMOOTH MUSCLE; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; URINARY DYSFUNCTION; URINE INCONTINENCE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; CYTOPROTECTION; DIABETES MELLITUS; HUMANS; KATP CHANNELS; LIGANDS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, CARDIAC; OBESITY; PANCREAS; PATENTS AS TOPIC;

EID: 79952057244     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.553601     Document Type: Review

References (101)

1. Seino S, Mikit T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol 2003;81:133-76 (Pubitemid 36141258)
2. Jahangir A, Terzic A. KATP channel therapeutics at the bedside J Mol Cell Cardiol 2005;39(1):99-112
3. Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol 1999;61:337-62 (Pubitemid 29143174)
4. Bond CT, Ammala C, Ashfield R, et al Cloning and functional expression of the cDNA encoding an inwardly-rectifying potassium channel expressed in pancreatic beta-cells and in the brain. FEBS Letter 1995;367(1):61-6
5. Clement JP, Kunjilwar K, Gonzalez G, et al Association and stoichiometry of K (ATP) channel subunits. Neuron 1997;18(5):827-38 (Pubitemid 27232792)
6. Babenko AP, Aguilar-Bryan L, Bryan J. A view of Sur/Kir6.x, KATP channels. Annu Rev Physiol 1998;60:667-87
7. Inagaki N, Gonoi T, Clement JP, et al A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels. Neuron 1996;16(5):1011-7 (Pubitemid 26171205)
8. Isomoto S, Kondo C, Yamada M, et al A novel sulphonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel. J Biol Chem 1996;271(40):24321-4 (Pubitemid 26333158)
9. Zhang HL, Bolton TB. Two types of ATP-sensitive potassium channels in rat portal vein smooth muscle cells. Br J Pharmacol 1996;118:105-14 (Pubitemid 26131253)
10. Inoue I, Nagase H, Kishi K, Higuti T. ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature 1991;352:244-47 (Pubitemid 21912326)
11. Paucek P, Mironova G, Mahdi E, et al Reconstruction and partial purification of the glibenclamide-sensitive, ATP-dependent K+ channel from rat liver and beef heart mitochondria. J Biol Chem 1992;267:26062-69 (Pubitemid 23014017)
12. Bajgar R, Seetharaman S, Kowaltowski AJ, et al Identyfication and properties of a novel intracellular (mitochondrial) ATP-sensitive potassium channel in brain. J Biol Chem 2001;276:33369-74
13. Cancherini DV, Trabuco LG, Reboucas NA, Kowaltowski AJ. ATP-sensitive K+ channels in renal mitochondria. Am J Physiol Renal Physiol 2003;285:F1291-6
14. Debska G, Kicinska A, Skalska J, et al Opening of potassium channels modulates mitochondrial function in rat skeletal muscle. Biochim Biophys Acta 2002;1556:97-105 (Pubitemid 35379667)
15. Halestrap AP. The regulation of the matrix volume of mammalian mitochondria in vivo and in vitro and its role in the control of mitochondrial metabolism. Biochim Biophys Acta 1989;973:355-82 (Pubitemid 19073722)
16. Ashcroft FM, Harrison DE, Ashcroft SJ. Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. Nature 1984;312:446-8 (Pubitemid 15217837)
17. Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic b-cell. Prog Biophys Mol Biol 1989;54:87-143
18. Gopel SO. Regulation of glucagons release in mouse-cells by KATP channels and inactivation of TTX-sensitive Na+ Channels. J Physiol 2000;528:509-20
19. Gopel SO, Kanno T, Barg S, Rorsman P. Patch-clamp characterization of somatostatin-secreting - cells in intact mouse pancreatic islets. J Physiol 2000;528:497-507
20. Nichols CG, Koster JC, Remedi MS. beta-cell hyperexcitability: from hyperinsulinism to diabetes. Diabetes Obes Metab 2007;9(Suppl 2):81-8
21. Ashcroft FM, ATP-sensitive potassium channelopathies. focus on insulin secretion. J Clin Invest 2005;115:2047-58 (Pubitemid 41134141)
22. Dunne MJ, Cosgrove KE, Shepherd RM,et al Hyperinsulinism in infancy: from basic science to clinical disease. Physiol Rev 2004;84(1):239-75 (Pubitemid 38049881)
23. Abraham MR, Jahangir A, Alekseev AE, Terzic A. Channelopathies of inwardly rectifying potassium channels. FASEB J 1999;13(14):1901-10 (Pubitemid 29517620)
24. De Tullio P, Lebrun P, Florence X, et al Selective pancreatic ATP-sensitive-potassium channel openers for the treatment of glucose homeostasis disorder. Drugs Fut 2006;31:991-1001 (Pubitemid 46165992)
25. Teramoto N. Physiological roles of ATP-sensitive K+ channels in smooth muscle. J Physiol 2006;572(Pt 3):617-24
26. Curley M, Cairns MT, Friel AM, et al Expression of mRNA transcripts for ATP-sensitive potassium channels in human myometrium. Mol Hum Reprod 2002;8:941-5 (Pubitemid 35174929)
27. Insuk SO, Chae MR, Choi JW, et al Molecular basis and characteristics of KATP channel in human corporal smooth muscle cells. Int J Impot Res 2003;15(4):258-66 (Pubitemid 37101659)
28. Haynes JM, Cook AL. Protein kinase G-induced activation of K(ATP) channels reduces contractility of human prostate tissue. Prostate 2006;66:377-85 (Pubitemid 43346948)
29. Davies NW. Modulation of ATP-sensitive K+ channels in skeletal muscle by intracellular protons. Nature 1990;343(6256):375-7
30. El-Hashim AZ, Buchheit KH, Fozard J, Page C. Effect of the K+(ATP) channel opener, KCO912, on baseline and allergen induced airway hyperresponsiveness in allergic rabbits. Eur J Pharmacol 2004;484(2-3):351-6 (Pubitemid 38117229)
31. Pelaia G, Gallelli L, Vatrella A, et al Potential role of potassium channel openers in the treatment of asthma and chronic obstructive pulmonary disease. Life Sci 2002;70(9):977-90 (Pubitemid 34085090)
32. Ramnarine SI, Liu YC, Rogers DF. Neuroregulation of mucus secretion by opioid receptors and K(ATP) and BK (Ca) channels in ferret trachea in vitro. Br J Pharmacol 1998;123(8):1631-8 (Pubitemid 28182046)
33. Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 2004;84:935-86 (Pubitemid 38823771)
34. Gopalakrishnan M, Shieh CC, Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders. Exp Opin Ther Targets 2004;8:437-58 (Pubitemid 39359650)
35. Noma A. ATP-regulated K+ channels in cardiac muscle. Nature 1983;305:147-8
36. Grover GJ, Garlid KD. ATP-sensitive potassium channels: a review of their cardioprotective pharmacology. J Mol Cell Cardiol 2000;32:677-95 (Pubitemid 30658936)
37. Kane GC, Liu XK, Yamada S, et al Cardiac KATP channels in health and disease. J Mol Cell Cardiol 2005;38(6):937-43 (Pubitemid 40725941)
38. Kubo M, Quayle JM, Standen NB. Angiotensin II inhibition of ATP-sensitive K+ currents in rat arterial smooth muscle cells through protein kinase C. J Physiol 1997;503(Pt 3):489-96 (Pubitemid 27496663)
39. Bienengraeber M, Olson TM, Selivanov VA, et al ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat Genet 2004;36(4):382-7 (Pubitemid 38437261)
40. Gok S, Vural K, Sekuri C, et al Effects of the blockade of cardiac sarcolemmal ATP-sensitive potassium channels on arrhythmias and coronary flow in ischaemia-reperfusion model in isolated rat hearts. Vascul Pharmacol 2006;44(4):197-205 (Pubitemid 43351178)
41. Facundo HT, Fornazari M, Kowaltowski AJ. Tissue protection mediated by mitochondrial K+ channels. Biochim Biophys Acta 2006;1762:202-12 (Pubitemid 43006026)
42. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischaemia-reperfusion injury. Physiol Rev 2008;88:581-609 (Pubitemid 351520088)
43. Cole W, McPherson C, Sontag D. ATP-regulated K+ channels protect the myocardium against ischaemia/ reperfusion damage. Circ Res 1991;69:571-81
44. Knopp A, Thierfelder S, Doepner B, Benndorf K. Mitochondria are the main ATP source for a cytosolic pool controlling the activity of ATP-sensitive K(+) channels in mouse cardiac myocytes. Cardiovasc Res 2001;52(2):236-45 (Pubitemid 33000400)
45. Sato T, Sasaki N, ORourke B, Marban E. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. J Am Coll Cardiol 2000;35(2):514-8 (Pubitemid 30125546)
46. Yao Z, Gross GJ. Effects of the KATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation 1994;89(4):1769-75
47. Grover GJ, McCullough JR, DAlonzo AJ, et al Cardioprotective profile of the cardiac-selective ATPsensitive potassium channel opener BMS-180448. J Cardiovasc Pharmacol 1995;25(1):40-50
48. Kulawiak B, Kudin AP, Szewczyk A, Kunz WS. BK channel openers inhibit ROS production of isolated rat brain mitochondria. Exp Neurol 2008;212:543-7
49. Czyz A, Szewczyk A, Nalecz MJ, Wojtczak L. The role of mitochondrial potassium fluxes in controlling the protonmotive force in energized mitochondria, Biochem Biophys Res Commun 1995;210:98-104
50. Testai L, Rapposelli S, Calderone V. Cardiac ATP-sensitive potassium channels: a potential target for an anti-ischaemic pharmacological strategy. Cardiovasc Hematol Agents Med Chem 2007;5(1):79-90 (Pubitemid 46062424)
51. Ardehali H, Chen Z, Ko Y, et al Multiprotein complex containing succinate dehydrogenase confers mitochondrial ATP-sensitive K+ channel activity, Proc Natl Acad Sci USA 2004;101:11880-5 (Pubitemid 39095388)
52. ORourke B. Evidence for mitochondrial K+ channels and their role in cardioprotection. Circ Res 2004;94:420-32
53. Busija DW, Lacza Z, Rajapakse N, et al Targeting mitochondrial ATP-sensitive potassium channels-a novel approach to neuroprotection. Brain Res Brain Res Rev 2004;46:282-94 (Pubitemid 39574329)
54. ORourke B. Myocardial KATP channels in preconditioning, Circ Res 2000;87:845-55
55. Bajgar R, Seetharaman S, Kowaltowski AJ, et al Identification and properties of a novel intracellular (mitochondrial) ATP-sensitive potassium channel in brain. J Biol Chem 2001;276(36):33369-74
56. Kis B, Nagy K, Snipes JA, et al The mitochondrial K(ATP) channel opener BMS-191095 induces neuronal preconditioning. Neuroreport 2004;15(2):345-9 (Pubitemid 38297363)
57. Chi X, Sutton ET, Hellermann G, Price JM. Potassium channel openers prevent beta-amyloid toxicity in bovine vascular endothelial cells. Neurosci Lett 2000;290:9-12 (Pubitemid 30488850)
58. Correia SC, Santos RX, Perry G, et al Mitochondria: The missing link between preconditioning and neuroprotection. J Alz Disease 2010; 20(Suppl 2):475-85
59. Zhang S, Ding JH, Zhou F, et al Iptakalim ameliorates MPP+-induced astrocyte mitochondrial dysfunction by increasing mitochondrial complex activity besides opening mitoK(ATP) channels. J Neurosci Res 2009;87(5):1230-9
60. Mazarati A. ATP-dependent potassium channels: a converging target for endogenous anticonvulsant factors. Epilepsy Curr 2005;5(4):139-41
61. Lohmann AB, Welch SP. ATP-gated K (+) channel openers enhance opioid antinociception: indirect evidence for the release of endogenous opioid peptides. Eur J Pharmacol 1999;385:119-27
62. Ocana M, Cendán CM, Cobos EJ, et al Potassium channels and pain: present realities and future opportunities. Eur J Pharmacol 2004;500:203-19 (Pubitemid 39304009)
63. Alekseev AE, Reyes S, Yamada S, et al Sarcolemmal ATP-sensitive K+ channels control. Energy expenditure determining body weight. Cell Metab 2010;11:58-69
64. Cardoso AR, Cabral-Costa JV, Kowaltowski AJ. Effects of a high fat diet on liver mitochondria: increased ATP-sensitive K+ channel activity and reactive oxygen species generation. J Bioenerg Biomembr 2010;42:245-53
65. Mannhold R. Structure-activity relationships of K(ATP) channel openers. Curr Top Med Chem 2006;6(10):1031-47 (Pubitemid 43796964)
66. Wang H, Tang Y, Wang L, et al ATP-sensitive potassium channel openers and 2,3-dimethyl-2-butylamine derivatives. Curr Med Chem 2007;14(2):133-65
67. Lawson K. Potassium channel openers as potential therapeutic weapons in ion channel disease. Kidney Int 2000;57:838-45 (Pubitemid 30434774)
68. Solvay Pharmaceuticals GMBH. Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators. WO2007125048; 2007
69. Solvay Pharmaceuticals GMBH. Use of CBX cannabinoid receptor modulators as potassium channel modulators. WO2007125049; 2007
70. Cota D, Marsicano G, Tschop M, et al The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112(3):423-31 (Pubitemid 38063771)
71. Hansen JB. Towards selective Kir6.2/ SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. Curr Med Chem 2006;13(4):361-76
72. Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related compounds. WO2010093243, 2010
73. Universita di Pisa. Pharmacodynamic hybrids endowed of hypoglicaemic and NO-donor activities obtained combining hydroxylated derivatives of glibenclamide and nitrooxy-substituted carboxylic acids. WO2008017925, 2008
74. Calderone V, Rapposelli S, Martelli A, et al NO-glibenclamide derivatives: prototypes of a new class of nitric oxide-releasing anti-diabetic drugs. Bioorg Med Chem 2009;17:5426-32
75. Auspex Pharmaceuticals, Inc. Sulfonylurea inhibitors of ATP-sensitive potassium channels. US20100056546; 2010
76. Auspex Pharmaceuticals, Inc. Sulfonylurea inhibitors of ATP-sensitive potassium channels. US20100130615; 2010
77. Auspex Pharmaceuticals, Inc. Benzoic acid inhibitors of ATP-sensitive potassium channels. US20100120861; 2010
78. Auspex Pharmaceuticals, Inc. Phenylalanine amide inhibitors of ATP-sensitive potassium channels. WO2010060041; 2010
79. Essentialis Inc. Salts of potassium ATP channel openers and uses thereof. US20100028429; 2010
80. Essentialis Inc. Pharmaceutical formulations of potassium ATP channel openers and use thereof. US20090149451; 2009
81. Albert Einstein College of Medicine of Yeshiva University, Signum Pharmaceutical Inc. Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels. WO2006088875; 2006
82. Herlands L, Pocai A, Rossetti L. Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels. US20070026079; 2007
83. Albert Einstein College of Medicine of Yeshiva University. Modulation of hypothalamic ATP-sensitive potassium channels. US20090012067; 2009
84. Universitàdi Pisa. Nitrogenous N-substituted 4-spiro-heterocyclic 2,2-dimethylchromane derivatives. WO2008007210; 2008
85. Calderone V, Testai L, Martelli A, et al Anti-ischaemic properties of a new spiro-cyclic benzopyran activator of the cardiac mitoKATP channel. Biochem Pharmacol 2010;79:39-47
86. Rapposelli S, Calderone V, Cirilli R, et al Enantioselectivity in Cardioprotection induced by (S)-(-)-2,2- Dimethyl-N-(4¢-acetamido-benzyl)- 4- spiromorpholone-chromane. J Med Chem 2009;52(5):1477-80
87. Breschi MC, Calderone V, Digiacomo M, et al Spirocyclic Benzopyran-based derivatives as new anti-ischaemic activators of mitochondrial ATP-sensitive potassium channel. J Med Chem 2008;51(21):6945-54
88. Hybernation Therapeutics Ltd. Organ protection, preservation and recovery. US20100256083; 2010
89. University of Rochester. Chemical preconditioning as a preventative or treatment for excitotoxic synaptic damage. WO2007053514; 2007
90. Zhang X, Qiu Y, Li X, et al Discovery and structure-activity relationships of a novel series of benzopyran-based KATP openers for urge urinary incontinence. Bioorg Med Chem 2009;17:855-66
91. Zhang X, Sui Z. Novel tricyclic dihydropyrazines as potassium channel openers. US20070191382; 2007
92. Janssen Pharmaceutica NV. Novel tricyclic dihydropyrazines as potassium channel openers. WO2007095424; 2007
93. Janssen Pharmaceutica NV. Novel pyridine derivatives as potassium ion channel openers. WO2006091800; 2006
94. Janssen Pharmaceutica NV. Novel coumarin derivatives as ion channel openers. WO2006078833; 2006
95. Janssen Pharmaceutica NV. Novel benzopyran derivatives as potassium channel openers. WO2007027780; 2007
96. Janssen Pharmaceutica NV. Novel quinoline derivatives as potassium ion channel openers. WO2006091769; 2006
97. Lanter JC, Sui Z. 3,4-diamino-3- cyclobutene-1,2-dione derivatives as potassium channel openers. US20090312412; 2009
98. Zhang X, Sui Z. Novel pyrazolylquinazolinones as potassium channel openers. US20070197566; 2007
99. Shenyang Pharmaceutical University. Application of chromane HEF-05 in relaxation of vascular smooth muscles. CN101829081; 2010
100. Shenyang Pharmaceutical University. New medical application of chromane compound HEF-05. CN101618033; 2010
101. Region Hovedstaden Glostrup Hospital, Olesen IJ, Olesen J. Treatment of migraine and headaches. WO2007009462; 2007